91,020 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Erste Asset Management GmbH

Erste Asset Management GmbH purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 91,020 shares of the medical research company's stock, valued at approximately $21,505,000. Erste Asset Management GmbH owned 0.05% of IQVIA at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. FMR LLC grew its stake in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of IQVIA in the 3rd quarter worth approximately $147,683,000. 1832 Asset Management L.P. raised its stake in shares of IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock worth $96,487,000 after acquiring an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in IQVIA in the second quarter valued at approximately $70,610,000. Finally, Impax Asset Management Group plc grew its holdings in IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock worth $344,998,000 after purchasing an additional 264,555 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IQV. Evercore ISI decreased their price objective on IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Royal Bank of Canada reiterated an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research note on Friday, November 1st. The Goldman Sachs Group dropped their price target on IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Leerink Partners reaffirmed an "outperform" rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, Robert W. Baird dropped their target price on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating on the stock in a research report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IQVIA has an average rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Stock Performance

IQV stock traded down $0.59 during trading on Friday, hitting $200.84. 513,717 shares of the company traded hands, compared to its average volume of 2,104,433. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The stock's 50-day simple moving average is $218.67 and its 200 day simple moving average is $226.17. The company has a market cap of $36.45 billion, a PE ratio of 26.36, a P/E/G ratio of 2.07 and a beta of 1.51.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.